For general GLP-1 onset timelines and understanding when each medication reaches full effect, those resources provide additional context that helps with transition planning
Higher doses generally improve appetite suppression, which can support greater calorie reduction but weight loss does not always accelerate linearly with each dose increase
People with severe pancreatitis history require physician guidance before using GLP-1 medications
Some doctors taper to 1.7mg or even 1.0mg and monitor weight stability
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity), a phase 3 study involving 17,604 adults with overweight or obesity and pre-existing CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% compared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48]
These do not match any common compounded vial concentration
